Surfactant Replacement Therapy

  • Fernando Moya
  • Maria-Cristina Javier


Continuous Positive Airway Pressure Respiratory Distress Syndrome Congenital Diaphragmatic Hernia Congenital Diaphragmatic Hernia Pulmonary Surfactant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. Blanco O, Perez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: role of the different components in an efficient pulmonary surfactant. Eur J Pharmacol. 2007;568:1–15.PubMedCrossRefGoogle Scholar
  2. El Shahed AI, Dargaville P, Ohlsson A, Soll RF. Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev. 2007;(3):CD002054.Google Scholar
  3. Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R. An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv. 2010;23:303–9.PubMedCrossRefGoogle Scholar
  4. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J. 1999;13:1455–76.PubMedCrossRefGoogle Scholar
  5. Jobe AH. Pharmacology review: why surfactant works for respiratory distress syndrome. NeoReviews. 2006;7:e95–106.CrossRefGoogle Scholar
  6. Kribs A, Hartel C, Kattner E, et al. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Paediatr. 2010;222:13–7.CrossRefGoogle Scholar
  7. Lally KP, Lally PA, Langham MR, Hirschl R, et al. Congenital Diaphragmatic Hernia Study Group. Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia. J Pediatr Surg. 2004;39:829–33.PubMedCrossRefGoogle Scholar
  8. Laughon M, Bose C, Moya F, et al. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics. 2009;123(1):89–96.PubMedCrossRefGoogle Scholar
  9. Morley CJ, Davis PG, Doyle LW, et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008;358:700–8.PubMedCrossRefGoogle Scholar
  10. Moya F, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005;115:1018–29.PubMedCrossRefGoogle Scholar
  11. Moya F, Javier MC. Myth. All surfactants are alike. Semin Fetal Neonatal Med. 2011;16(5):269–74.PubMedCrossRefGoogle Scholar
  12. Moya F, Maturana A. Animal-derived surfactants versus past and current synthetic surfactants: current status. Clin Perinatol. 2007;34:145–77.PubMedCrossRefGoogle Scholar
  13. Notter RH. Lung surfactant: basic science and clinical applications. New York: Marcel Dekker Inc.; 2000.Google Scholar
  14. Perez-Gil J, Keough KM. Interfacial properties of surfactant proteins. Biochim Biophys Acta. 1998;1408:203–17.PubMedGoogle Scholar
  15. Pfister RH, Soll R, Wiswell TE. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2009;(4):CD006180.Google Scholar
  16. Pfister RH, Soll RF, Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2007;(4):CD006069.Google Scholar
  17. Sandri F, Plavka R, Ancore G, et al. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics. 2010;125:e1402–9.PubMedCrossRefGoogle Scholar
  18. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database of Syst Rev 2009;2:Art. No.: CD007836. doi:10.1002/14651858.CD007836.Google Scholar
  19. Sinha SK, Lacaze-Masmonteil T, Valls I, Soler A, et al. A randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005;115:1030–8.PubMedCrossRefGoogle Scholar
  20. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007;(4):CD003063.Google Scholar
  21. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Network. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362:1970–8.CrossRefGoogle Scholar
  22. Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med. 2002;347:2141–8.PubMedCrossRefGoogle Scholar
  23. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005;5:58–68.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of NeonatologyNew Hanover Regional Medical Center, Coastal Carolina Neonatology, PLLCWilmingtonUSA

Personalised recommendations